New ESRD bundled payment system considered

Article Overview

This article covers CMS and congressional discussion of a potential bundled payment system for End Stage Renal Disease care, along with the broader Medicare policy context around spending on ESRD-related anemia drugs and a proposed national coverage decision involving off-label use. It is relevant for readers tracking Medicare reimbursement policy, renal care payment models, and coverage developments that may affect providers, patients, and payers. The piece also places the discussion in the setting of federal oversight, possible demonstration requirements, and physician fee schedule concerns.